Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Pevarello

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Pharmaceutical Patent Analyst|November 19, 2015
FFA4/GPR120 agonists: a survey of the recent patent literatureRosa Formicola, Paolo Pevarello, Christina Kuhn, et al.
Pharmaceutical Patent Analyst|March 2, 2017
P2X7 antagonists for CNS indications: recent patent disclosuresPaolo Pevarello, Silvia Bovolenta, Paola Tarroni, et al.
Journal of Chemical Information and Modeling|September 27, 2005
Structure-based approaches to improve selectivity: CDK2-GSK3beta binding site analysisAnna Vulpetti, Patrizia Crivori, Alexander Cameron, et al.
Pharmaceutical Patent Analyst|November 19, 2013
IP issues facing researchers by Gino D'OcaOrn Almarsson, Mauro Angiolini, Jonathan Baell, et al.
Advances in Experimental Medicine and Biology|June 23, 2004
Modulation of the kynurine pathway of tryptophan metabolism in search for neuroprotective agents. Focus on kynurenine-3-hydroxylaseRoberto Pellicciari, Laura Amori, Gabriele Costantino, et al.
International Journal of Molecular Sciences|October 13, 2021
Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse ModelSavina Apolloni, Paola Fabbrizio, Susanna Amadio, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2005
Benzodipyrazoles: a new class of potent CDK2 inhibitorsRoberto D'Alessio, Alberto Bargiotti, Suzanne Metz, et al.
Plos One|November 2, 2012
Fragment-hopping-based discovery of a novel chemical series of proto-oncogene PIM-1 kinase inhibitorsGustavo Saluste, Maria I Albarran, Rosa M Alvarez, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2005
3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitorsPaolo Pevarello, Daniele Fancelli, Anna Vulpetti, et al.
Journal of Medicinal Chemistry|February 10, 2010
Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitorsGabriella Traquandi, Marina Ciomei, Dario Ballinari, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Pharmaceutical Patent Analyst|November 19, 2015
FFA4/GPR120 agonists: a survey of the recent patent literatureRosa Formicola, Paolo Pevarello, Christina Kuhn, et al.
Pharmaceutical Patent Analyst|March 2, 2017
P2X7 antagonists for CNS indications: recent patent disclosuresPaolo Pevarello, Silvia Bovolenta, Paola Tarroni, et al.
Journal of Chemical Information and Modeling|September 27, 2005
Structure-based approaches to improve selectivity: CDK2-GSK3beta binding site analysisAnna Vulpetti, Patrizia Crivori, Alexander Cameron, et al.
Pharmaceutical Patent Analyst|November 19, 2013
IP issues facing researchers by Gino D'OcaOrn Almarsson, Mauro Angiolini, Jonathan Baell, et al.
Advances in Experimental Medicine and Biology|June 23, 2004
Modulation of the kynurine pathway of tryptophan metabolism in search for neuroprotective agents. Focus on kynurenine-3-hydroxylaseRoberto Pellicciari, Laura Amori, Gabriele Costantino, et al.
International Journal of Molecular Sciences|October 13, 2021
Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse ModelSavina Apolloni, Paola Fabbrizio, Susanna Amadio, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2005
Benzodipyrazoles: a new class of potent CDK2 inhibitorsRoberto D'Alessio, Alberto Bargiotti, Suzanne Metz, et al.
Plos One|November 2, 2012
Fragment-hopping-based discovery of a novel chemical series of proto-oncogene PIM-1 kinase inhibitorsGustavo Saluste, Maria I Albarran, Rosa M Alvarez, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2005
3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitorsPaolo Pevarello, Daniele Fancelli, Anna Vulpetti, et al.
Journal of Medicinal Chemistry|February 10, 2010
Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitorsGabriella Traquandi, Marina Ciomei, Dario Ballinari, et al.
Pageof 3